» Articles » PMID: 20237813

Characteristic Effect of an Anticancer Dinuclear Platinum(II) Complex on the Higher-order Structure of DNA

Overview
Publisher Springer
Specialty Biochemistry
Date 2010 Mar 19
PMID 20237813
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

It is known that a 1,2,3-triazolato-bridged dinuclear platinum(II) complex, [{cis-Pt(NH(3))(2)}(2)(micro-OH)(micro-1,2,3-ta-N (1),N (2))](NO(3))(2) (AMTA), shows high in vitro cytotoxicity against several human tumor cell lines and circumvents cross-resistance to cisplatin. In the present study, we examined a dose- and time-dependent effect of AMTA on the higher-order structure of a large DNA, T4 phage DNA (166 kbp), by adapting single-molecule observation with fluorescence microscopy. It was found that AMTA induces the shrinking of DNA into a compact state with a much higher potency than cisplatin. From a quantitative analysis of the Brownian motion of individual DNA molecules in solution, it became clear that the density of a DNA segment in the compact state is about 2,000 times greater than that in the absence of AMTA. Circular dichroism spectra suggested that AMTA causes a transition from the B to the C form in the secondary structure of DNA, which is characterized by fast and slow processes. Electrophoretic measurements indicated that the binding of AMTA to supercoiled DNA induces unwinding of the double helix. Our results indicate that AMTA acts on DNA through both electrostatic interaction and coordination binding; the former causes a fast change in the secondary structure from the B to the C form, whereas the latter promotes shrinking in the higher-order structure as a relatively slow kinetic process. The shrinking effect of AMTA on DNA is attributable to the possible increase in the number of bridges along a DNA molecule. It is concluded that AMTA interacts with DNA in a manner markedly different from that of cisplatin.

Citing Articles

Azolato-Bridged Dinuclear Platinum(II) Complexes Exhibit Androgen Receptor-Mediated Anti-Prostate Cancer Activity.

Arai T, Oshima M, Uemura M, Matsunaga T, Ashizawa T, Suhara Y Inorg Chem. 2024; 63(44):20951-20963.

PMID: 39258898 PMC: 11539055. DOI: 10.1021/acs.inorgchem.4c01093.


Different Effects of Cisplatin and Transplatin on the Higher-Order Structure of DNA and Gene Expression.

Kishimoto T, Yoshikawa Y, Yoshikawa K, Komeda S Int J Mol Sci. 2019; 21(1).

PMID: 31861648 PMC: 6981875. DOI: 10.3390/ijms21010034.


Investigations of the binding of [Pt2(DTBPA)Cl2](II) and [Pt2(TPXA)Cl2](II) to DNA via various cross-linking modes.

Yue H, Yang B, Wang Y, Chen G Int J Mol Sci. 2013; 14(10):19556-86.

PMID: 24077126 PMC: 3821573. DOI: 10.3390/ijms141019556.

References
1.
Reedijk J . Medicinal applications of heavy-metal compounds. Curr Opin Chem Biol. 1999; 3(2):236-40. DOI: 10.1016/s1367-5931(99)80037-4. View

2.
Rye H, Yue S, Wemmer D, Quesada M, Haugland R, Mathies R . Stable fluorescent complexes of double-stranded DNA with bis-intercalating asymmetric cyanine dyes: properties and applications. Nucleic Acids Res. 1992; 20(11):2803-12. PMC: 336925. DOI: 10.1093/nar/20.11.2803. View

3.
Chaney S, Campbell S, Bassett E, Wu Y . Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol. 2004; 53(1):3-11. DOI: 10.1016/j.critrevonc.2004.08.008. View

4.
Poklar N, Pilch D, Lippard S, Redding E, Dunham S, Breslauer K . Influence of cisplatin intrastrand crosslinking on the conformation, thermal stability, and energetics of a 20-mer DNA duplex. Proc Natl Acad Sci U S A. 1996; 93(15):7606-11. PMC: 38793. DOI: 10.1073/pnas.93.15.7606. View

5.
Bruijnincx P, Sadler P . New trends for metal complexes with anticancer activity. Curr Opin Chem Biol. 2007; 12(2):197-206. PMC: 2923029. DOI: 10.1016/j.cbpa.2007.11.013. View